Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SPX-303 + trastuzumab deruxtecan
- Development stage
- Unknown
- Lead developer
- SparX Biotech
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
SPX-303 + trastuzumab deruxtecan is a combination therapy being developed by SparX Biotech. It consists of SPX-303, a bispecific antibody targeting Leukocyte Immunoglobulin-Like Receptor B2 (LILRB2) and Programmed Death-Ligand 1 (PD-L1), and trastuzumab deruxtecan (Enhertu), a HER2-directed antibody-drug conjugate (ADC). SPX-303 is designed to reprogram the immunosuppressive tumor microenvironment by blocking LILRB2 on myeloid cells and inhibiting the PD-1/PD-L1 checkpoint. Trastuzumab deruxtecan provides targeted delivery of a topoisomerase I inhibitor payload to HER2-expressing tumor cells. The combination is currently in Phase 1 clinical trials for the treatment of solid tumors, aiming to leverage the synergistic effects of immune checkpoint inhibition and ADC-mediated cytotoxicity.
- Brand names
- Enhertu
- Other names
- LILRB2 x PD-L1 + EnhertuLILRB2-PD-L1-bispecific antibody combination + EnhertuLILRB2 x PD-L1 + Enhertu-SparX Biotech-LILRB2-PD-L1-bispecific antibody combination
02
Targets
LILRB2 (Leukocyte immunoglobulin-like receptor subfamily B member 2)ERBB2 (Erb-b2 receptor tyrosine kinase 2)CD274 (Programmed cell death protein 1 ligand 1)TOP1 (DNA Topoisomerase I)
Beyond the preview
Go deeper on SPX-303 + trastuzumab deruxtecan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SPX-303 + trastuzumab deruxtecan.